RY 169.51 -1.1719% SHOP 175.85 -3.2036% TD 85.4 -0.187% ENB 59.6 -1.715% BN 84.78 -1.4873% TRI 250.65 2.1186% CNQ 43.69 0.9007% CP 110.72 -0.5926% CNR 146.88 0.7891% BMO 142.84 -0.6054% BNS 72.34 -0.0829% CSU 4896.4902 0.1981% CM 87.07 -0.9668% MFC 45.08 6.5217% ATD 71.13 -0.6425% NGT 68.13 0.9932% TRP 64.42 -1.2872% SU 56.73 -0.0176% WCN 266.69 -0.146% L 176.74 -1.5157%
Last update at 2025-02-20T19:17:00Z
Maravai LifeSciences Acquires Assets and Intellectual Property from Molecular Assemblies
Tue 28 Jan 25, 09:01 PMThree Top Undervalued Small Caps In US With Insider Buying
Wed 22 Jan 25, 10:05 AMMaravai LifeSciences Holdings, Inc. (MRVI) Stock: An Under $5 Gem with Biggest Upside Potential
Tue 21 Jan 25, 04:02 AMMaravai LifeSciences Announces Preliminary Unaudited 2024 Revenue
Wed 08 Jan 25, 09:10 PMMaravai Lifesciences initiated with a Neutral at Guggenheim
Fri 20 Dec 24, 12:15 PMExploring December 2024's Undervalued Small Caps With Insider Action In US
Thu 19 Dec 24, 10:04 AMMaravai LifeSciences Appoints R. Andrew Eckert as Chairman of the Board of Directors
Thu 05 Dec 24, 09:05 PMExploring ACNB And 2 More Undervalued Small Caps With Insider Buying In US
Wed 20 Nov 24, 10:05 AMMaravai LifeSciences Announces November 2024 Investor Conference Schedule
Tue 12 Nov 24, 01:05 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 551.47M | 530.76M | 81.70M | -5.85300M | -16.49800M |
| Minority interest | -270.45800M | -287.21300M | 66.23M | 3.23M | 3.61M |
| Net income | 490.66M | 469.25M | 88.97M | -5.20100M | -17.73100M |
| Selling general administrative | 129.26M | 100.06M | 94.25M | 48.35M | 41.19M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 714.04M | 658.68M | 204.45M | 76.29M | 63.07M |
| Reconciled depreciation | 38.10M | 24.75M | 25.84M | 24.08M | 22.35M |
| Ebit | 574.22M | 554.64M | 67.60M | 23.99M | 17.46M |
| Ebitda | 568.40M | 543.67M | 93.43M | 48.51M | 39.81M |
| Depreciation and amortization | -5.82000M | -10.97000M | 25.84M | 24.52M | 22.35M |
| Non operating income net other | - | 0.28M | - | - | - |
| Operating income | 574.22M | 554.64M | 67.60M | 23.99M | 16.44M |
| Other operating expenses | 316.58M | 255.84M | 183.20M | 118.83M | 106.46M |
| Interest expense | 20.41M | 30.26M | 30.74M | 29.96M | 27.40M |
| Tax provision | 60.81M | 61.52M | 2.88M | -0.65200M | 0.42M |
| Interest income | 2.34M | - | - | - | - |
| Net interest income | -18.07600M | -30.26000M | -30.74000M | -29.95900M | -27.39900M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 60.81M | 61.52M | 2.88M | -0.65200M | 0.42M |
| Total revenue | 883.00M | 799.24M | 284.10M | 143.14M | 123.83M |
| Total operating expenses | 147.63M | 115.28M | 103.55M | 51.98M | 45.69M |
| Cost of revenue | 168.96M | 140.56M | 79.65M | 66.85M | 60.77M |
| Total other income expense net | -22.74400M | -23.88000M | 14.10M | -29.84100M | -6.47400M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 490.66M | 469.25M | 78.82M | -5.20100M | -16.91500M |
| Net income applicable to common shares | 220.21M | 182.04M | 76.89M | -8.48600M | -17.73100M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 1487.45M | 2282.32M | 1918.28M | 1270.69M | 577.80M |
| Intangible assets | 220.99M | 216.66M | 117.57M | 177.66M | 197.85M |
| Earning assets | - | - | - | - | - |
| Other current assets | 17.83M | 25.80M | 19.70M | 11.10M | 3.62M |
| Total liab | 697.57M | 1377.07M | 1372.91M | 1115.94M | 433.17M |
| Total stockholder equity | 416.75M | 545.22M | 315.50M | 88.51M | 141.40M |
| Deferred long term liab | - | 2.20M | 2.70M | 3.40M | - |
| Other current liab | 60.53M | 89.36M | 65.69M | 38.55M | 18.74M |
| Common stock | 2.51M | 2.55M | 2.55M | 2.58M | 183.91M |
| Capital stock | 2.51M | 2.55M | 2.55M | 2.58M | 183.91M |
| Retained earnings | 285.74M | 404.77M | 184.56M | 0.85M | -42.38100M |
| Other liab | - | 693.38M | 713.64M | 400.36M | 15.90M |
| Good will | 326.03M | 283.67M | 152.77M | 224.28M | 224.28M |
| Other assets | - | 806.13M | 812.47M | 435.86M | 0.81M |
| Cash | 574.96M | 632.14M | 551.27M | 236.18M | 24.70M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 87.47M | 110.14M | 93.78M | 130.78M | 29.56M |
| Current deferred revenue | 3.36M | 3.09M | 10.21M | 78.06M | 0.84M |
| Net debt | 36.01M | -46.87600M | -16.95900M | 354.60M | 365.50M |
| Short term debt | 12.85M | 11.71M | 9.72M | 6.00M | 2.50M |
| Short long term debt | 5.44M | 5.44M | 6.00M | 6.00M | 2.50M |
| Short long term debt total | 610.97M | 585.26M | 534.31M | 590.78M | 390.20M |
| Other stockholder equity | 128.50M | 137.90M | 128.39M | 85.12M | 7.97M |
| Property plant equipment | - | 116.59M | 46.33M | 101.31M | 94.31M |
| Total current assets | 699.91M | 847.90M | 740.04M | 331.60M | 60.55M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | 44.89M | 315.50M | -313.42000M | -280.73200M |
| Short term investments | - | - | - | - | - |
| Net receivables | 55.72M | 146.81M | 117.51M | 51.02M | 18.03M |
| Long term debt | 518.71M | 522.00M | 524.59M | 528.61M | 334.78M |
| Inventory | 51.40M | 43.15M | 51.56M | 33.30M | 14.20M |
| Accounts payable | 10.73M | 5.99M | 8.15M | 8.17M | 7.48M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | 229.86M | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | - | - | - | -0.04400M | -0.13300M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | 2.55M | 2.58M | 183.91M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | 184.56M | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 9.32M | 51.69M | 53.45M | 4.16M | 0.81M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 787.54M | 1434.41M | 1178.24M | 939.09M | 517.24M |
| Capital lease obligations | 86.82M | 57.83M | 3.72M | 56.17M | 52.92M |
| Long term debt total | - | - | 524.59M | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -267.61200M | 105.66M | 6.07M | -17.14800M | -3.45100M |
| Change to liabilities | -8.70100M | -7.30200M | 78.40M | 2.55M | -1.67000M |
| Total cashflows from investing activities | -267.61200M | 105.66M | 6.07M | -17.14800M | -3.45100M |
| Net borrowings | -5.44000M | -6.00000M | 196.92M | -2.64000M | 55.43M |
| Total cash from financing activities | -187.49900M | -159.04900M | 53.21M | -4.16700M | -9.16700M |
| Change to operating activities | -23.56800M | -17.49100M | 9.74M | 1.52M | -12.33600M |
| Net income | 490.66M | 469.25M | 78.82M | -5.20100M | -16.91500M |
| Change in cash | 80.87M | 315.09M | 211.48M | 2.83M | -12.87300M |
| Begin period cash flow | 551.27M | 236.18M | 24.70M | 21.87M | 34.74M |
| End period cash flow | 632.14M | 551.27M | 236.18M | 24.70M | 21.87M |
| Total cash from operating activities | 535.98M | 368.57M | 152.19M | 24.11M | -0.18600M |
| Issuance of capital stock | 0.00000M | 0.00000M | 1758.93M | - | 0.00000M |
| Depreciation | 38.10M | 24.75M | 25.84M | 24.08M | 22.35M |
| Other cashflows from investing activities | -12.17300M | 120.50M | -12.17300M | -12.17300M | 0.16M |
| Dividends paid | - | 153.45M | -609.32100M | 97.05M | 52.06M |
| Change to inventory | 9.46M | -21.57400M | -19.09900M | 0.11M | 2.31M |
| Change to account receivables | -22.27200M | -70.39100M | -33.14400M | -1.88800M | -4.14600M |
| Sale purchase of stock | 0.00000M | 1.71M | -1457.98200M | - | 0.00000M |
| Other cashflows from financing activities | -173.60400M | -153.04900M | 773.66M | -1.52700M | 298.09M |
| Change to netincome | 319.96M | 45.83M | -0.34000M | 0.48M | -3.71800M |
| Capital expenditures | 17.09M | 14.85M | 25.41M | 17.15M | 3.61M |
| Change receivables | - | -70.39100M | - | - | - |
| Cash flows other operating | - | -68.26000M | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | 315.18M | - | - | - |
| Change in working capital | -45.08200M | -176.63100M | 35.89M | 2.29M | -15.84100M |
| Stock based compensation | 18.67M | 10.46M | 24.63M | 1.68M | 2.12M |
| Other non cash items | -8.69500M | -6.16300M | -7.52400M | 2.42M | 7.79M |
| Free cash flow | 518.89M | 353.72M | 126.78M | 6.97M | -3.79700M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| MRVI Maravai Lifesciences Holdings Inc |
0.04 1.10% | 4.12 | - | 30.40 | 7.31 | 2.67 | 3.98 | 1.61 |
| NVO Novo Nordisk A/S |
0.31 0.37% | 83.71 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
1.01 1.22% | 83.81 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
7.45 1.58% | 479.21 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
11.20 1.63% | 696.86 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
10770 Wateridge Circle, San Diego, CA, United States, 92121
| Name | Title | Year Born |
|---|---|---|
| Mr. Carl W. Hull | Co-Founder and Exec. Chairman & Interim CEO | 1959 |
| Mr. Kevin M. Herde | Exec. VP & CFO | 1972 |
| Mr. Kurt Oreshack | Exec. VP, Gen. Counsel & Sec. | 1981 |
| Ms. Christine Dolan | Chief Operating Officer of Biologics Safety Testing | 1968 |
| Mr. Brian Neel | Chief Operating Officer of Nucleic Acid Production | 1976 |
| Dr. Peter Michael Leddy Ph.D. | Exec. VP & Chief Admin. Officer | 1963 |
| Ms. Debra Hart | Sr. Director of Investor Relations | NA |
| Ms. Doreen Pippen | VP of Marketing | NA |
| Mr. Carl W. Hull | Co-Founder & Executive Chairman | 1959 |
| Mr. William E. Martin III | Chief Executive Officer | 1976 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
CA 
AU
UK
US
NZ
Please wait processing your request...